A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-10
DOI
10.1007/s00228-021-03149-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries
- (2019) Guy De Backer et al. ATHEROSCLEROSIS
- Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Pre-Specified Secondary End Points in ORION 1
- (2018) Kausik K. Ray et al. CIRCULATION
- Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
- (2018) Sreeneeranj Kasichayanula et al. CLINICAL PHARMACOKINETICS
- PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review
- (2018) Yehuda Handelsman et al. Journal of the American Heart Association
- Inhibiting PCSK9 — biology beyond LDL control
- (2018) Robert M. Stoekenbroek et al. Nature Reviews Endocrinology
- The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
- (2017) Christine Landlinger et al. EUROPEAN HEART JOURNAL
- Treatment of Cholesterol in 2017
- (2017) Harlan M. Krumholz JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of Intensive LDL Cholesterol Lowering on Coronary Artery Atherosclerosis Progression
- (2017) Sanghoon Shin et al. JACC-Cardiovascular Imaging
- Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia
- (2017) Peter P. Toth et al. Journal of the American Heart Association
- A Phase I Randomized Study of a Specifically Engineered, pH-Sensitive PCSK9 Inhibitor RN317 (PF-05335810) in Hypercholesterolemic Subjects on Statin Therapy
- (2016) M Levisetti et al. CTS-Clinical and Translational Science
- Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study
- (2016) John J.P. Kastelein et al. EUROPEAN HEART JOURNAL
- 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
- (2016) Alberico L. Catapano et al. EUROPEAN HEART JOURNAL
- Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials
- (2016) Michel Farnier et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Interpretation of the evidence for the efficacy and safety of statin therapy
- (2016) Rory Collins et al. LANCET
- ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
- (2015) John J.P. Kastelein et al. EUROPEAN HEART JOURNAL
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management
- (2014) Gergana Galabova et al. PLoS One
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation